Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche’s Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
CymaBay Therapeutics Long-term Open Label Study Finds Treatment With Seladelpar For Two Years Improves Key Liver Biomarkers In Patients With PBC
Study results presented at The Liver Meeting® 2021 demonstrated continued reductions in biomarkers of cholestasis and hepatocellular injury over two years
Seladelpar generally appeared safe with low rates
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.
Raymond James Maintains Strong Buy on CymaBay Therapeutics, Raises Price Target to $14
Raymond James analyst Steven Seedhouse maintains CymaBay Therapeutics (NASDAQ:CBAY) with a Strong Buy and raises the price target from $12 to $14.
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
‘2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10’ -TipRanks
https://www.tipranks.com/news/article/2-strong-buy-penny-stocks-that-could-rally-all-the-way-to-10/
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)